TL;DR
- 1.Most concussions resolve in 10 to 14 days. Post-concussion syndrome is defined by symptoms lasting beyond four weeks and affects 15 to 30 percent of concussion patients, per a 2023 StatPearls review. Standard rest-and-wait care has essentially no evidence base once symptoms cross the three-month mark.
- 2.A 2015 paper in the journal Brain Injury formally proposed renaming PCS to Post-Inflammatory Brain Syndrome (PIBS), arguing that sustained neuroinflammation, not structural injury, drives chronic symptoms. Most clinicians have not absorbed this. The peptide protocols that work target the actual mechanism.
- 3.SS-31 reversed mitochondrial dysfunction and cut neuronal apoptosis in a 2018 TBI rodent model by restoring cardiolipin function on the inner mitochondrial membrane. BPC-157 reduced subarachnoid hemorrhage and brain edema in Sikric et al.'s 2009 Regulatory Peptides study. Neither has completed a human PCS trial.
- 4.BDNF Val66Met Met carriers show larger neuroinflammation volumes and more tau accumulation after repeated mild TBI versus Val/Val carriers, per a 2019 Frontiers in Neurology study. APOE4 carriers clear amyloid-beta more slowly. Either variant extends your expected recovery window.
- 5.On July 23-24, 2026, the FDA Pharmacy Compounding Advisory Committee voted 8-6 to recommend BPC-157 for the 503A bulks list. That vote is non-binding. Final rulemaking takes a year or more. As of today, BPC-157 remains a research-grade compound for most US users.
Post-concussion syndrome can last 18 months or longer in a subset of patients. Your neurologist's baseline advice, rest then watchful waiting, has essentially zero evidence base once symptoms pass the three-month mark. The biology changes after the first few weeks, and the protocol needs to change with it.
This article covers the week-by-week neurological timeline, what is actually happening in the brain at each stage, and which peptides are mechanistically matched to which phase. We also cover why your BDNF and APOE4 genetics may be the single most important predictor of how long this takes for you specifically.
Percentage of concussion patients who develop post-concussion syndrome, defined as symptoms persisting beyond four weeks. A 2023 StatPearls review of post-concussion literature put the range at 15 to 30 percent, with higher rates in patients over 40 and those with prior concussion history.
The standard definition of PCS is simple: one or more concussion symptoms persisting beyond the expected recovery window of 10 to 14 days. In practice, clinicians typically use four weeks as the diagnostic threshold. After that, you enter PCS territory and the standard playbook stops working.
Here is the thing nobody in mainstream neurology is talking about yet. A 2015 paper in the journal Brain Injury formally proposed renaming PCS to "Post-Inflammatory Brain Syndrome" or PIBS. The argument was specific: the driver of chronic symptoms is not structural damage, not psychological vulnerability, and not malingering. It is sustained neuroinflammation. Microglial cells that should calm down after the acute injury phase instead remain chronically activated, releasing cytokines that suppress BDNF, dysregulate HPA axis output, and maintain the cognitive and mood symptoms indefinitely. The research exists. The rename has not caught on. But the implication is significant: you are treating the wrong thing if you are treating PCS as a structural or rest-based problem.
Think of your brain after a concussion like a city after a flood. The flood itself lasts a few hours. But the cleanup crew, once activated, can keep disrupting traffic for months if they stay in emergency mode. In PCS, the microglial "cleanup cells" do not turn off. They keep releasing inflammation signals that suppress memory, slow processing speed, and maintain anxiety. That is the real problem. Peptides that switch off the cleanup crew, or that restore the repair signals the crew is blocking, are the ones that move the needle.
What is actually happening in your brain week by week?
The neuroscience of concussion recovery falls into four phases with distinct biology and distinct intervention windows. Standard care treats all four phases the same way. That is the fundamental mismatch that leaves chronic PCS patients without good options.
| Phase | Duration | Primary Biology | Core Symptoms | Best-Matched Peptide |
|---|---|---|---|---|
| Acute | Days 0 to 14 | Excitotoxicity, oxidative burst, blood-brain barrier disruption, mitochondrial failure | Headache, dizziness, light/noise sensitivity, confusion | SS-31 (mitochondrial rescue), BPC-157 (vascular) |
| Subacute | Weeks 2 to 12 | Microglial activation peak, BDNF suppression, cortisol dysregulation, neuroinflammation | Brain fog, cognitive slowing, mood instability, sleep disruption | BPC-157 (BDNF + NOS), Selank (cortisol + BDNF) |
| Chronic | Months 3 to 12 | Persistent low-grade neuroinflammation, HPA dysregulation, reduced neuroplasticity | Fatigue, persistent fog, anxiety, sensitivity to stress | Selank, Semax, BPC-157 maintenance |
| Refractory | 12+ months | Possible glymphatic backlog, synaptic pruning deficits, structural white matter changes | Treatment-resistant fog, sleep-wake disruption, executive dysfunction | Selank + Semax stack, SS-31 re-introduction |
The most important insight in that table: the acute phase window closes at two weeks. Everything you do in the first 14 days has outsized impact because that is when the biology is most plastic. Miss that window and you are managing a more entrenched inflammatory state.
Week 1 to 4: The window nobody tells you about
In the first hours after a concussion, two parallel processes start. First, excitotoxicity: neurons fire uncontrollably and flood the synapse with glutamate, causing calcium overload and cell death in the injury penumbra. Second, mitochondrial failure: the energy production machinery in neurons collapses under oxidative stress, cutting off ATP supply to cells that need it most to survive.
SS-31 (elamipretide) is the only compound in the peptide toolkit with direct published evidence for this second problem. A 2018 study in Oxidative Medicine and Cellular Longevity (PMC6129854) found that SS-31 reversed mitochondrial dysfunction in a rat TBI model by binding cardiolipin on the inner mitochondrial membrane. Cardiolipin stabilizes the electron transport chain. After TBI, cardiolipin gets oxidized and the chain collapses. SS-31 restored it. Neuronal apoptosis markers dropped significantly. Neurological deficit scores improved. The mechanism is clean and the evidence base is there.
BPC-157 addresses the vascular side of the acute phase. A 2009 study by Sikric et al. in Regulatory Peptides showed BPC-157 reduced subarachnoid and intraventricular hemorrhage in a direct brain impact model, attenuated brain edema, and preserved neurological function. The proposed mechanism runs through eNOS activation and VEGFR2 upregulation, both of which support vascular repair and blood flow restoration to hypoxic tissue. Read the full BPC-157 TBI research breakdown if you want the mechanism detail.
The practical implication: if you have access to SS-31 and BPC-157 in the days immediately following a concussion, you have two mechanistically distinct tools targeting two different failure modes. Most users do not have this access in the acute window because they do not yet know the injury will become PCS. By the time they start researching peptides, they are already in the subacute or chronic phase.
Month 1 to 3: Why standard care fails the chronic group
This is where the split between "normal recovery" and "PCS" happens. For 70 to 85 percent of patients, the neuroinflammation resolves on its own over the first few weeks and symptoms fade. For the remaining 15 to 30 percent, microglial activation persists, BDNF levels stay suppressed, and the symptom cluster of fog, mood instability, and fatigue becomes the new baseline.
Standard care for this group is, bluntly, inadequate. Rest works for the acute phase. Sub-threshold aerobic exercise is the best-supported intervention for accelerating recovery in the subacute phase, per the 2023 StatPearls review. But neither directly addresses the neuroinflammation mechanism that is driving chronic symptoms.
SS-31 significantly reduced markers of secondary brain injury, including malondialdehyde levels and neuronal apoptosis, while improving mitochondrial membrane potential and ATP production in the injured hemisphere. Neurological deficit scores improved significantly compared to vehicle-treated controls at all measured timepoints.
Oxidative Medicine and Cellular Longevity, PMC6129854, 2018
BPC-157 becomes more relevant in this phase for a specific reason: its BDNF upregulation mechanism. The fog and cognitive slowing of PCS correlate with suppressed BDNF, which is driven by the elevated cortisol output from the dysregulated HPA axis. BPC-157 raises BDNF through a pathway that does not depend on exercise-induced BDNF secretion, which means it works even when the patient's activity tolerance is limited by symptoms. The complete mechanism is covered in our article on SS-31 vs BPC-157 for neuroprotection.
Selank enters the picture here for a different reason. The anxiety, mood instability, and sleep disruption that define the subacute PCS symptom cluster are partly driven by GABA-A receptor dysregulation after injury. Selank modulates GABA-A and serotonergic signaling without the receptor downregulation that makes benzodiazepines problematic for long-term use. It also upregulates BDNF through the cortisol-suppression pathway, removing the chronic stress signal that blocks BDNF transcription. The detail on that mechanism is in our article on how Selank increases BDNF.
Month 3 and beyond: What recovery actually looks like in the chronic phase
If symptoms persist past three months, you are in chronic PCS. The biology has shifted again. Active excitotoxicity and the acute inflammatory cascade are over. What remains is a lower-grade but persistent neuroinflammatory state, HPA axis dysregulation, and in some cases early evidence of glymphatic clearance failure: the brain's overnight cleaning system is not fully clearing metabolic waste, including amyloid-beta and tau.
The glymphatic system runs primarily during sleep. Chronic PCS patients almost universally report sleep disruption. The connection is not incidental. Disrupted sleep impairs glymphatic clearance, which allows neuroinflammatory debris to accumulate, which worsens symptoms, which further disrupts sleep. This is a cycle that rest alone cannot break.
For the chronic phase, the Semax-Selank combination addresses two separate bottlenecks. Semax raises BDNF through direct BDNF pathway activation, not just cortisol removal. Selank maintains GABA-A function and removes the ongoing cortisol suppression of BDNF. Running both addresses BDNF from two directions simultaneously. See why the intranasal route delivers these peptides to the brain within two minutes, which is relevant for Semax and Selank specifically since both are primarily used intranasally.
Binds cardiolipin on the inner mitochondrial membrane. Restores electron transport chain function. Most relevant in the acute phase (days 0 to 14) when mitochondrial failure is the primary driver of neuronal death. Also indicated in the chronic refractory phase when mitochondrial dysfunction has become a persistent feature.
Suppresses destructive iNOS while upregulating protective eNOS. Reduces brain edema and hemorrhage in acute models. Drives BDNF upregulation in the subacute phase. Most useful in the transition from acute to subacute and through the first three months. Access in the US remains in a regulatory gray zone as of mid-2026.
Removes the cortisol-driven suppression of BDNF transcription. Modulates GABA-A and serotonergic signaling without receptor downregulation. Most relevant in the subacute and chronic phases where HPA dysregulation is driving the anxiety, fog, and sleep disruption cluster. Accessible via prescription in the US.
Why BDNF Val66Met and APOE4 predict how long this takes
Two genetic variants predict PCS recovery speed more reliably than injury severity, age, or prior concussion history. Knowing yours changes the protocol in specific ways.
BDNF Val66Met is the clearer predictor. A 2019 study in Frontiers in Neurology (Allen et al., PMC6854037) found that Met allele carriers showed larger neuroinflammation volumes, more p-tau accumulation, and increased microglial activation after repeated mild TBI versus Val/Val carriers. The mechanism is at the secretion level: Met allele carriers have impaired activity-dependent BDNF release. Under the stress of a brain injury, their BDNF output is constrained from both sides: the injury suppresses it top-down via cortisol, and the Val66Met variant limits the secretion response bottom-up.
The relative increase in neuroinflammation volume and tau accumulation seen in BDNF Val66Met Met carriers after repeated mild TBI compared to Val/Val carriers, per a 2019 Frontiers in Neurology study. Met carriers represent approximately 30 percent of the general population.
APOE4 operates through a different mechanism. It slows amyloid-beta clearance from the brain and impairs vascular repair after injury. APOE4 carriers have higher baseline neuroinflammation in general, and after a concussion that elevated inflammatory state amplifies the secondary injury cascade. In practice, APOE4 carriers entering the chronic PCS phase are dealing with a higher inflammatory burden than non-carriers on the same protocol.
NOS3 is the third variable. T-allele carriers at rs1799983 produce less baseline endothelial nitric oxide. Since BPC-157's primary brain mechanism runs through eNOS activation, the peptide matters more for T-allele carriers specifically because they are starting from a lower eNOS baseline. Pairing BPC-157 with a complete understanding of BPC-157 dosing and routes is particularly important for NOS3 T-allele carriers who want to maximize the vascular repair mechanism.
The peptide protocol by phase: a practical timeline
The honest caveat before this table: no human RCT has tested any peptide specifically for PCS. Every protocol recommendation here is extrapolated from animal TBI data and mechanism logic. That is the current state of the field. Practitioners who use these compounds off-label do so on the strength of preclinical mechanistic evidence, not approved indications.
| Phase | Peptide | Route | Dose Range | Protocol Notes |
|---|---|---|---|---|
| Acute (days 0-14) | SS-31 | Subcutaneous injection | 1 to 4 mg/day | Most time-sensitive window. Mitochondrial rescue is most impactful early. |
| Acute (days 0-14) | BPC-157 | Subcutaneous injection | 250 to 500 mcg/day | Targets vascular repair and edema reduction. Can run alongside SS-31. |
| Subacute (weeks 2-12) | BPC-157 | Subcutaneous or intranasal | 250 to 500 mcg/day | BDNF upregulation takes 1 to 3 weeks to build. Do not expect immediate cognitive effect. |
| Subacute (weeks 2-12) | Selank | Intranasal | 250 to 500 mcg per session | Most useful for the anxiety and sleep disruption cluster. Combines well with BPC-157. |
| Chronic (months 3+) | Selank + Semax | Intranasal | 250 to 500 mcg each | Two-pronged BDNF approach. Selank removes the cortisol block. Semax activates the pathway directly. |
| Refractory (12+ months) | SS-31 re-introduction | Subcutaneous injection | 1 to 4 mg/day | Reintroduce if mitochondrial symptoms dominate: fatigue, exercise intolerance, cognitive slow recovery. |
BPC-157 access in 2026: what actually changed
The regulatory picture on BPC-157 is actively evolving. On July 23-24, 2026, the FDA Pharmacy Compounding Advisory Committee voted 8-6 to recommend BPC-157 for placement on the 503A bulks list. If finalized, this would restore licensed compounding pharmacy access under physician prescription, the same channel that existed before October 2023.
The key word is "if finalized." The PCAC vote is advisory, not binding. Formal placement on the 503A list requires a notice-and-comment rulemaking process that typically takes a year or more after the committee recommendation. As of today, BPC-157 is not legally available through US compounding pharmacies. Research-grade supply is commercially accessible, but that access channel does not carry prescription oversight or manufacturing quality standards.
SS-31 (elamipretide) received FDA approval for Barth syndrome in September 2025, making it the first approved mitochondria-targeting drug. That approval does not extend to neurological indications, but it does mean the compound now has a prescription access pathway. Selank and Semax are accessible through licensed compounding pharmacies under prescription as of mid-2026, with no current compounding restrictions on either.
Verdict: Post-concussion syndrome is a neuroinflammation problem, and the protocol should treat it like one. The recovery timeline is not uniform. The acute phase closes at two weeks and represents the highest-impact intervention window. The subacute phase is where the chronic vs. recovery split happens. BPC-157 and Selank are the best-supported tools for that window based on preclinical evidence. BDNF Val66Met and APOE4 genetics predict who takes longest and whose protocol should run longer and combine more peptides. If you want to know your specific genetic profile before starting a protocol, our DNA upload tool or saliva kit delivers a ranked peptide report based on your actual genotype.
Your DNA shapes how you respond to the peptides discussed above.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
How long does post-concussion syndrome last on average?
Most concussions resolve in 10 to 14 days. Post-concussion syndrome, defined as symptoms persisting beyond four weeks, affects 15 to 30 percent of concussion patients per a 2023 StatPearls review. Of those who develop PCS, the majority recover within three to six months. A smaller subset, roughly 10 to 15 percent of PCS patients, remain symptomatic beyond one year. The single strongest predictors of a longer timeline are BDNF Val66Met Met allele status and APOE4 carrier status.
What peptides help with post-concussion syndrome?
The three peptides with the strongest mechanistic case for PCS are SS-31, BPC-157, and Selank. SS-31 targets mitochondrial dysfunction in the acute phase by restoring cardiolipin function. BPC-157 reduces brain edema and activates the eNOS vascular repair pathway, then raises BDNF in the subacute phase. Selank removes the chronic cortisol suppression of BDNF and modulates GABA-A signaling for the anxiety and sleep disruption cluster. None of these have completed human PCS trials. All recommendations are extrapolated from animal TBI data.
When should I start a peptide protocol after a concussion?
The acute window of days 0 to 14 is the highest-impact intervention period. SS-31 and BPC-157 are most relevant here for mitochondrial rescue and vascular repair respectively. In practice, most people do not research peptides until they are already in the subacute or chronic phase because they did not expect a single concussion to become PCS. If you are past the acute window, the subacute protocol of BPC-157 and Selank is still strongly supported mechanistically for months two through twelve.
Does BPC-157 cross the blood-brain barrier?
BPC-157 at roughly 1,419 Da is above the passive diffusion cutoff for the blood-brain barrier. However, two factors complicate the clean answer. First, after brain injury the BBB is temporarily more permeable, potentially allowing access that would not exist in a healthy brain. Second, the intranasal route bypasses the BBB entirely via the olfactory nerve, reaching the brain within two minutes per radiotracer studies. For neurological protocols specifically, intranasal delivery removes the BBB question from the equation.
How does APOE4 affect concussion recovery time?
APOE4 carriers clear amyloid-beta and neuroinflammatory debris more slowly from the brain after injury. They also have higher baseline neuroinflammation, which amplifies the secondary injury cascade after concussion. In practice, APOE4 carriers in the chronic PCS phase are managing a higher inflammatory burden than non-carriers even on the same protocol. Protocols that address both BDNF upregulation and neuroinflammation are more strongly indicated for APOE4 carriers than a single-peptide approach.
Is post-concussion syndrome the same as a traumatic brain injury?
No, but they share mechanisms. TBI is the injury event itself and can range from mild concussion to severe brain damage. Post-concussion syndrome is the persistence of symptoms after a mild TBI beyond the expected recovery window. The research that informs PCS peptide protocols comes primarily from animal TBI models, which use more severe injury paradigms than a typical concussion. The mechanistic overlap is strong enough to apply the findings directionally to PCS, but the severity and dose relationships should be interpreted conservatively.
What is the difference between PCS and PIBS?
PIBS, or Post-Inflammatory Brain Syndrome, is the alternative name proposed in a 2015 Brain Injury journal paper. The authors argued that the term PCS incorrectly implies the condition is a psychological sequela of concussion, which has historically led to underdiagnosis and inadequate treatment. PIBS emphasizes that the mechanism is sustained neuroinflammation, which has direct therapeutic implications: treatments that target inflammation and BDNF suppression, including the peptide protocols covered here, are more rationally indicated than rest alone.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.